



29 December 2021

Australian Securities Exchange Announcement

Data Licensing Deal with Alto Neuroscience

Total Brain Limited (“Total Brain,” or “TTB” or “the Company”), a digital mental health SaaS company, advises the market that the Company has entered a perpetual, non-exclusive license with Alto Neuroscience, Inc. for its iSpot-D (International Study to Predict Optimized Treatment for Depression) research data, effective immediately.

Total Brain will receive a one-off license fee of USD \$500K payable USD \$100k by 15 January 2022 and USD \$400k within 15 days of the data transfer date which is estimated to occur before 31 March 2022. The transaction is subject to conventional commercial termination provisions.

Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. Amit Etkin, M.D., Ph.D., founder and chief executive officer of Alto Neuroscience added, “Members of the Alto team have a deep knowledge of the iSPOT-D study having acquired, worked with and published on its data in the past and have the breadth of expertise necessary to harness its unique value. Alto’s AI-enabled platform and data science team are ideally positioned to extract meaningful insights from the data for our clinical-stage drug development pipeline.”

Authorised on behalf of the Total Brain board of directors by Non-Executive Director Matt Morgan.

For further queries, please contact:

Investor

Simon Poidevin
President – Australia & New Zealand
E: simon.poidevin@totalbrain.com

Media

Nigel Kassulke
Managing Director, Teneo Consulting
E: nigel.kassulke@teneo.com
M: +61 (0) 407 904 874

About Total Brain Limited (ASX: TTB)

Total Brain Limited is a San Francisco and Sydney-based company that has developed and offers Total Brain, a mental health monitoring and support platform powered by the world's largest standardized brain database. Its SaaS platform has helped more than 1 million registered users to-date scientifically measure and optimize their brain capacities while managing the risk of common mental conditions. Benefits for employers and payers include better mental healthcare access, lower costs and higher productivity. Benefits for providers include improved patient outcomes, tracking of evidence-based outcomes across the continuum of care, and a reduction in clinician fatigue. For more information, please visit www.totalbrain.com and follow us on [Twitter](#), [LinkedIn](#) and [Facebook](#).

About Alto Neuroscience

Alto Neuroscience is pioneering precision psychiatry by developing targeted medicines to help patients get better faster. For more information, visit www.altoneuroscience.com or contact the company at corporate@altoneuroscience.com.